FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204108803> ?p ?o ?g. }

• W3204108803 endingPage "e458" @default.
• W3204108803 startingPage "e450" @default.
• W3204108803 abstract "Abstract Background Remdesivir (RDV) improved clinical outcomes among hospitalized patients with coronavirus disease 2019 (COVID-19) in randomized trials, but data from clinical practice are limited. Methods We examined survival outcomes for US patients hospitalized with COVID-19 between August and November 2020 and treated with RDV within 2 days of hospitalization vs those not receiving RDV during their hospitalization using the Premier Healthcare Database. Preferential within-hospital propensity score matching with replacement was used. Additionally, patients were also matched on baseline oxygenation level (no supplemental oxygen charges [NSO], low-flow oxygen [LFO], high-flow oxygen/noninvasive ventilation [HFO/NIV], and invasive mechanical ventilation/extracorporeal membrane oxygenation [IMV/ECMO]) and 2-month admission window and excluded if discharged within 3 days of admission (to exclude anticipated discharges/transfers within 72 hours, consistent with the Adaptive COVID-19 Treatment Trial [ACTT-1] study). Cox proportional hazards models were used to assess time to 14-/28-day mortality overall and for patients on NSO, LFO, HFO/NIV, and IMV/ECMO. Results A total of 28855 RDV patients were matched to 16687 unique non-RDV patients. Overall, 10.6% and 15.4% RDV patients died within 14 and 28 days, respectively, compared with 15.4% and 19.1% non-RDV patients. Overall, RDV was associated with a reduction in mortality at 14 days (hazard ratio [95% confidence interval]: 0.76 [0.70–0.83]) and 28 days (0.89 [0.82–0.96]). This mortality benefit was also seen for NSO, LFO, and IMV/ECMO at 14 days (NSO: 0.69 [0.57–0.83], LFO: 0.68 [0.80–0.77], IMV/ECMO: 0.70 [0.58–0.84]) and 28 days (NSO: 0.80 [0.68–0.94], LFO: 0.77 [0.68–0.86], IMV/ECMO: 0.81 [0.69–0.94]). Additionally, HFO/NIV RDV group had a lower risk of mortality at 14 days (0.81 [0.70–0.93]) but no statistical significance at 28 days. Conclusions RDV initiated upon hospital admission was associated with improved survival among patients with COVID-19. Our findings complement ACTT-1 and support RDV as a foundational treatment for hospitalized COVID-19 patients." @default.
• W3204108803 created "2021-10-11" @default.
• W3204108803 creator A5000473129 @default.
• W3204108803 creator A5015721926 @default.
• W3204108803 creator A5025609858 @default.
• W3204108803 creator A5025776157 @default.
• W3204108803 creator A5050215213 @default.
• W3204108803 creator A5058012378 @default.
• W3204108803 creator A5058715015 @default.
• W3204108803 creator A5060710888 @default.
• W3204108803 creator A5066096917 @default.
• W3204108803 creator A5069074902 @default.
• W3204108803 creator A5078169203 @default.
• W3204108803 creator A5088020557 @default.
• W3204108803 date "2021-10-01" @default.
• W3204108803 modified "2023-10-17" @default.
• W3204108803 title "Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort" @default.
• W3204108803 cites W3027630905 @default.
• W3204108803 cites W3032394272 @default.
• W3204108803 cites W3032677067 @default.
• W3204108803 cites W3037972133 @default.
• W3204108803 cites W3043870823 @default.
• W3204108803 cites W3048176840 @default.
• W3204108803 cites W3048478051 @default.
• W3204108803 cites W3080480399 @default.
• W3204108803 cites W3080718665 @default.
• W3204108803 cites W3092014403 @default.
• W3204108803 cites W3093604087 @default.
• W3204108803 cites W3097940531 @default.
• W3204108803 cites W3100727477 @default.
• W3204108803 cites W3106878713 @default.
• W3204108803 cites W3110466220 @default.
• W3204108803 cites W3110542218 @default.
• W3204108803 cites W3115009914 @default.
• W3204108803 cites W3117489874 @default.
• W3204108803 cites W3120594090 @default.
• W3204108803 cites W3120848145 @default.
• W3204108803 cites W3128649147 @default.
• W3204108803 cites W3137071766 @default.
• W3204108803 cites W3137844213 @default.
• W3204108803 cites W3165008380 @default.
• W3204108803 cites W4210642183 @default.
• W3204108803 doi "https://doi.org/10.1093/cid/ciab875" @default.
• W3204108803 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34596223" @default.
• W3204108803 hasPublicationYear "2021" @default.
• W3204108803 type Work @default.
• W3204108803 sameAs 3204108803 @default.
• W3204108803 citedByCount "76" @default.
• W3204108803 countsByYear W32041088032021 @default.
• W3204108803 countsByYear W32041088032022 @default.
• W3204108803 countsByYear W32041088032023 @default.
• W3204108803 crossrefType "journal-article" @default.
• W3204108803 hasAuthorship W3204108803A5000473129 @default.
• W3204108803 hasAuthorship W3204108803A5015721926 @default.
• W3204108803 hasAuthorship W3204108803A5025609858 @default.
• W3204108803 hasAuthorship W3204108803A5025776157 @default.
• W3204108803 hasAuthorship W3204108803A5050215213 @default.
• W3204108803 hasAuthorship W3204108803A5058012378 @default.
• W3204108803 hasAuthorship W3204108803A5058715015 @default.
• W3204108803 hasAuthorship W3204108803A5060710888 @default.
• W3204108803 hasAuthorship W3204108803A5066096917 @default.
• W3204108803 hasAuthorship W3204108803A5069074902 @default.
• W3204108803 hasAuthorship W3204108803A5078169203 @default.
• W3204108803 hasAuthorship W3204108803A5088020557 @default.
• W3204108803 hasBestOaLocation W32041088031 @default.
• W3204108803 hasConcept C126322002 @default.
• W3204108803 hasConcept C141071460 @default.
• W3204108803 hasConcept C17923572 @default.
• W3204108803 hasConcept C201903717 @default.
• W3204108803 hasConcept C207103383 @default.
• W3204108803 hasConcept C2776858399 @default.
• W3204108803 hasConcept C2777080012 @default.
• W3204108803 hasConcept C2779134260 @default.
• W3204108803 hasConcept C3008058167 @default.
• W3204108803 hasConcept C44249647 @default.
• W3204108803 hasConcept C50382708 @default.
• W3204108803 hasConcept C524204448 @default.
• W3204108803 hasConcept C71924100 @default.
• W3204108803 hasConceptScore W3204108803C126322002 @default.
• W3204108803 hasConceptScore W3204108803C141071460 @default.
• W3204108803 hasConceptScore W3204108803C17923572 @default.
• W3204108803 hasConceptScore W3204108803C201903717 @default.
• W3204108803 hasConceptScore W3204108803C207103383 @default.
• W3204108803 hasConceptScore W3204108803C2776858399 @default.
• W3204108803 hasConceptScore W3204108803C2777080012 @default.
• W3204108803 hasConceptScore W3204108803C2779134260 @default.
• W3204108803 hasConceptScore W3204108803C3008058167 @default.
• W3204108803 hasConceptScore W3204108803C44249647 @default.
• W3204108803 hasConceptScore W3204108803C50382708 @default.
• W3204108803 hasConceptScore W3204108803C524204448 @default.
• W3204108803 hasConceptScore W3204108803C71924100 @default.
• W3204108803 hasFunder F4320308573 @default.
• W3204108803 hasIssue "1" @default.
• W3204108803 hasLocation W32041088031 @default.
• W3204108803 hasLocation W32041088032 @default.
• W3204108803 hasLocation W32041088033 @default.
• W3204108803 hasOpenAccess W3204108803 @default.
• W3204108803 hasPrimaryLocation W32041088031 @default.

• next